VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Developing Alzheimer’s disease biomarkers based on retinal imaging

Chiara La Morgia, MD, PhD, IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy, talks on the promise of retinal imaging in Alzheimer’s disease. A large research focus is on the development of retinal biomarkers able to identify biological changes associated with Alzheimer’s and monitor disease progression over time. Optical coherence tomography (OCT) and OCT angiography are being assessed in this setting. This interview took place during the European Academy of Neurology 2021 congress.

Transcript (edited for clarity)

This is very promising data. Actually, there are a lot of groups looking at the potential using of OCT. I didn’t mention before, but we also run in this group of patients OCT studies and there is evidence of retinal nerve fiber layer thinning even in the early stage of the disease. But also there are also a lot of promising results about angiography or CT angiography, so looking at the vessels...

This is very promising data. Actually, there are a lot of groups looking at the potential using of OCT. I didn’t mention before, but we also run in this group of patients OCT studies and there is evidence of retinal nerve fiber layer thinning even in the early stage of the disease. But also there are also a lot of promising results about angiography or CT angiography, so looking at the vessels. And also, there is a group looking also at the possibility of evaluating the deposition of amyloid in vivo, using for example, curcumin. So, there are a lot of areas of development and the possible use of biomarker also for clinical studies or therapeutic interventions.

Read more...